Skip to content

To evaluate the Safety and efficacy of Unani formulations in the treatment of Amnesia.

Validation of Unani Pharmacopoeial formulations in Nisyan (Amnesia)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/09/003978
Enrollment
300
Registered
2013-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nisyan (Amnesia) Health Condition 2: R413- Other amnesia

Interventions

Intervention1: Majoon e Nisyan: 7grams once daily , orally in the morning Duration of treatment : 12 weeks Control Intervention1: NIL: NA

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of both sexes between 18 to 60 yrs. 2.Patients having classical signs and symptoms suggestive of the disease:- ï??(a)Loss of short-term memory ï??(b)Loss of past memory ï??(c)Mixed type of Memory loss ï??(d)Pseudo-event replacement memory. ï??(e)Loss of memory associated with Audio- Visual Haulicinations. ï??(f)Forgetfulness of particular event. ï??(g)In articulation in memory. ï??(h)In ability to write, partially or fully in previously writing people . ï??(i)In ability to read in literate people ï??(j)In ability to copy a design. ï??(k)Amnesia with Isolated Systolic Hypertension. ï??(l)Amnesia with Mild and Moderate hypertension.

Exclusion criteria

Exclusion criteria: 1. Brain Tumours 2. Stroke 3. Space Occupying brain lesions 4. Epilepsy. 5. Amnesia symptoms with D.M. 6. Patients with severe Hypertension. 7. Pt. on any drug related to CNS.

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptomsTimepoint: 12 weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safetyTimepoint: 12 WEEKS

Countries

India

Contacts

Public ContactDR ABDUL HANNAN

Central Council for Research in Unani Medicine (CCRUM),

ccrum605@gmail.com01128521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026